P/E ratio for ContraFect (CFRX)
P/E ratio as of May 2024 (TTM): -0.0009
According to ContraFect's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.00094038. At the end of 2022 the company had a P/E ratio of -0.0598.
P/E ratio history for ContraFect from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0598 | -98.73% |
| 2021 | -4.70 | 37.64% |
| 2020 | -3.41 | -22.53% |
| 2019 | -4.40 | 49.69% |
| 2018 | -2.94 | -12.6% |
| 2017 | -3.37 | 65.45% |
| 2016 | -2.03 | -54.16% |
| 2015 | -4.44 | 200.59% |
| 2014 | -1.48 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Viking Therapeutics
VKTX | -82.8 | 8,800,959.15% | 🇺🇸 USA |
 Recro Pharma
REPH | -2.79 | 296,234.46% | 🇺🇸 USA |
 Prometheus Biosciences RXDX | -56.8 | 6,039,532.91% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.